Table 2.

Results of multivariable Fine–Gray subdistribution analysis including risk-of-recurrence score-derived risk groups for predicting local recurrence-free survival (full period)

	Subhazard ratio	P
PgR status (positive versus negative)	0.46 (0.19, 1.10)	0.082
Age (per year)	0.98 (0.94, 1.03)	0.505
Grade (G2 or Gx versus G1)	0.73 (0.23, 2.32)	0.592
Node status (N1–N3 versus N0)	0.97 (0.39, 2.44)	0.951
PAM-50 risk group (high versus low)*	4.60 (1.99, 10.63)	< 0.001
Treatment (tamoxifen/anastozole†  versus tamoxifen alone‡)	1.00 (0.43, 2.31)	0.997
Tumour category (T2 or T3 versus T1)	0.72 (0.30, 1.74)	0.472

Values in parentheses are 95 per cent confidence intervals. The analysis included 1034 patients.

^*High risk, PAM-50 risk-of-recurrence score 57 or more.

^†Tamoxifen for 2–3 years followed by anastrozole for 2–3 years;

^‡tamoxifen for 5 years.